-
Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization GalleryModerna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization
3011, 2020
Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) [...]
2411, 2020
La Roche-Posay Presents the New Acne Diagnostic Tool Powered by Artificial Intelligence
Effaclar SpotScan is the result of 2 years of work [...]
1911, 2020
Dermatology Webinar Series
With the COVID-19 pandemic still causing disruption on a global [...]
1711, 2020
PDA supports campaign to protect all Retail Workers from Abuse, Threats and Violence
This National Respect for Shopworkers Week (16-22 November), the PDA [...]
